Rosetta Genomics Launches BRAF Mutation Assay
October 12 2015 - 7:30AM
Business Wire
Provides additional information to ensure that
oncologists can optimize treatment decisions for their cancer
patients
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces the launch of a molecular test for BRAF mutation analysis
to help personalize therapy for melanoma and colon cancer patients.
This newest assay will complement its broad offerings so that
oncologists can optimize treatment decisions for their cancer
patients.
Rosetta Genomics’ BRAF mutation analysis test utilizes highly
specific and sensitive Competitive Allele-Specific TaqMan® (CAST)
PCR™ technology that can detect as little as 0.5% mutated DNA in a
large, normal DNA sample. BRAF mutations occur in up to 50% of
malignant melanomas, and several FDA-approved BRAF inhibitor
therapies have been introduced to the market for use in patients
with late-stage metastatic melanoma.
“We are proud to be launching our sensitive BRAF mutation
analysis test as it enhances our portfolio of solid tumor profiling
tests, which leverage a broad array of genomics platforms to enable
personalized treatment of patients with cancer,” stated Kenneth A.
Berlin, President and Chief Executive Officer of Rosetta Genomics.
“The BRAF assay adds to the growing number of testing services we
provide, which further strengthens Rosetta Genomics as a leader in
delivering personalized diagnostic testing.”
About Rosetta Cancer Testing Service
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ can accurately identify the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta’s assays are designed to provide objective
diagnostic data. In the U.S. alone, Rosetta Genomics estimates that
150,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 patients from the Rosetta Kidney Cancer Test™ and
222,000 patients from the Rosetta Lung Cancer Test™. The Company’s
assays are offered directly by Rosetta Genomics in the U.S., and
through distributors around the world. In addition to its
proprietary products, the Company markets the Rosetta Genomics
OncoGxOne, OncoGxLung, PGxOne™ and EGFR and KRAS tests for Admera
Health. With the acquisition of PersonalizeDx, the Company now
offers a broader menu of molecular and other assays for bladder,
lung, prostate and breast cancer patients. For more information,
please visit www.rosettagenomics.com. Parties interested in
ordering any of these tests can contact Rosetta Genomics at (215)
382-9000 ext. 309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company offers core FISH, IHC and PCR-based
testing capabilities and partnerships in oncology and urology that
provide additional content and platforms that complement the
Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing
services are commercially available through the Philadelphia, PA-
and Lake Forest, CA-based CAP-accredited, CLIA-certified labs,
respectively. For more information visit
www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including but not limited
to statements relating to Rosetta’s BRAF assay increasing
oncologists’ ability to optimize treatment decisions for their
cancer patients, and the sensitivity of Rosetta’s BRAF assay,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s Annual Report
on Form 20-F for the year ended December 31, 2014 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151012005117/en/
Rosetta GenomicsKen Berlin, 609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestors:LHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2024 to May 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From May 2023 to May 2024